Inhibrx Ownership
| INBX Stock | USD 13.60 0.45 3.20% |
Shares in Circulation | First Issued 2018-03-31 | Previous Quarter 15.5 M | Current Value 15 M | Avarage Shares Outstanding 34.7 M | Quarterly Volatility 10.4 M |
Inhibrx |
Inhibrx Stock Ownership Analysis
About 27.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.53. Some equities with similar Price to Book (P/B) outperform the market in the long run. Inhibrx recorded earning per share (EPS) of 112.62. The entity had not issued any dividends in recent years. Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company was founded in 2010 and is headquartered in La Jolla, California. Inhibrx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 106 people. To learn more about Inhibrx call the company at 858 795 4220 or check out https://inhibrx.com.Besides selling stocks to institutional investors, Inhibrx also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Inhibrx's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Inhibrx's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Inhibrx Quarterly Liabilities And Stockholders Equity |
|
Inhibrx Insider Trades History
About 27.0% of Inhibrx are currently held by insiders. Unlike Inhibrx's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Inhibrx's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Inhibrx's insider trades
Inhibrx Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Inhibrx is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Inhibrx backward and forwards among themselves. Inhibrx's institutional investor refers to the entity that pools money to purchase Inhibrx's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Dekabank Deutsche Girozentrale | 2024-09-30 | 0.0 | Advisor Group Holdings, Inc. | 2024-09-30 | 0.0 |
Inhibrx Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Inhibrx insiders, such as employees or executives, is commonly permitted as long as it does not rely on Inhibrx's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Inhibrx insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Inhibrx Outstanding Bonds
Inhibrx issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Inhibrx uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Inhibrx bonds can be classified according to their maturity, which is the date when Inhibrx has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Inhibrx Corporate Filings
F3 | 2nd of April 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 1st of April 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 28th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 17th of March 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Inhibrx Stock Analysis
When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.